Rose Ventures

Rose Ventures works with early stage companies developing innovative, high-impact life science products and services We bring a wealth of direct operational expertise, a track record of success, and a network of life scientists, entrepreneurs and contacts in industry, academia, finance and government that can be leveraged to facilitate growth of the most promising emerging companies in the space Beyond financing or advisory services, portfolio companies and clients benefit by tapping into a network that can help them execute on their business plans and create value for all stake holders

Stanley D. Rose, Ph.D.

President and Managing Partner Stan Rose is a Ph D biologist, life sciences executive, and serial entrepreneur He has spent over three decades working with leading scientists and clinicians to create substantial commercial value from inventions related to genome analysis He has raised more than $100 million in startup funding and led businesses to create more than $1 billion in market value for shareholders, commercializing life science products impacting the lives of millions

Dr Rose currently serves on the Board of Invenra, a biotechnology company focused on the discovery and development of multi-specific antibodies for immuno-oncology and autoimmune disorders He also serves on the Board of Xeno Biosciences, a drug development company dedicated to finding safe and effective treatments for obesity and metabolic diseases Dr Rose is a Director of SerumDPT Bioscience, who have created the first device enabling real-time isolation of plasma or serum from drawn blood He also serves as a Senior Fellow with the Council on Strategic Risks, participating in The Alliance to End Biological Threats

Dr Rose was co-founder, President and CEO of Transplant Genomics Inc (acquired by Eurofins in 2019), whose TruGraf® blood gene expression tests enable doctors to rule out silent rejection in kidney transplant recipients

Dr Rose was a Director of Cellular Dynamics International (NASDAQ: ICEL), a leader in pluripotent stem cell technology for drug discovery and cell therapy (acquired by FujiFilm in 2015), and Chair of the Market Advisory Board for Cyvek, a protein immunoassay and immuno-diagnostics company (acquired by BioTechne in 2014)

Highlights from earlier in his career include serving as CEO of NimbleGen Systems, a genomics tools company, from 2003 through its acquisition by Roche in 2007; co-founding and growing Genetic MicroSystems, a microarray instrumentation company that was acquired by Affymetrix in 2000; and directing the PCR business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s

Dr Rose received his B A from Cornell University and his Ph D from the Massachusetts Institute of Technology